For appointments

Call the office

Folsom, California Office: 916-983-4444

Call Now

Close

WHO:

Dr. Gish is a Hepatologist specializing in all forms of liver disease, liver cancer and liver transplant. Dr. Gish has partnered with TeleMed2U to provide telemedicine consultative services for patients with liver disease.

WHAT:

TeleMed2U is a telemedicine-based multi-specialty clinical practice increasing access to specialist providers providing, “healthcare anywhere and everywhere.” The telemedicine consultation will be conducted through our HIPAA and HITECH compliant platform. Connectivity testing will be done in advance to ensure you can connect via our telemedicine platform. Following the consultation, a clinical note will be provided including a summary of your liver consultation with Dr. Gish and his consultative recommendations.

COST:

Payment will be processed through an online secure transaction portal. The fees for consultative services are:

Initial 60 minute consultation per patient: $500.00
Follow Up 30 minute consultation per patient: $300.00

NEXT STEPS:

If you’d like to continue, please click Next to complete the form and we will contact you to schedule connectivity testing. During the test you will have the opportunity to determine the method of providing medical records, discuss appointment availability as well as discuss any additional questions that you have. If you are a healthcare facility interested in services, please complete the form and we can discuss the options that are right for you and your patients.

Email

Subject

Country

You should be aware of the general risks of transmitting information over the Internet, which may not use encryption. You should therefore not share any personal medical information that you would wish to be held confidential in a physician/patient or similar clinical relationship.

The information contained on this website is not intended, should not substitute for, or be used instead of, a clinical or therapeutic relationship with a health care professional who is fully familiar with the specifics of your case. The information on this site may assist you in your personal, general research but none of it constitutes the practice of medicine or any other health care profession.

Nothing in this site is intended as a recommendation or endorsement of any specific tests, products, procedures, healthcare provider, opinions, or other information that may be mentioned in this site. Any reliance on any information provided by the website personnel, others appearing on the site at the invitation of the website and/or other visitors to the site is solely at the user's risk.

E-mail correspondence with Dr. Robert G. Gish Consultants, LLC or any of its employees, or agents, does not create a physician/patient relationship between us or cause Dr. Gish to create or retain any medical records about you, monitor your care, or communicate with your own health care provider.

Always seek the advice of your physician or other qualified health care provider with any questions you have regarding your medical care. If you suspect that you may have a medical condition, or are seeking medical advice or treatment, we recommend that you consult a qualified health professional as soon as possible.

Powered by

Close Form

Re: Removal of Vemlidy from CVS Health Formularies

Nov 20, 2025

Letter: Re: Removal of Vemlidy from CVS Health Formularies

Dear Mr. Joyner, Dr. Compton-Phillips, and Mr. DeVaney,

We have been made aware that Aetna CVS Health and CVS Caremark are instituting changes to their formulary plan and removing Vemlidy (tenofovir alafenamide, TAF) as a covered medication for treating chronic hepatitis B effective January 1st, 2026.

We, as caregivers and clinical thought leaders, ask that CVS Health add tenofovir alafenamide (TAF, Vemlidy) back onto its treatment formulary for hepatitis B, allowing the decision regarding hepatitis B treatment to be left to healthcare providers and their patients. Every patient with hepatitis B should have access to the best treatment that meets their individual needs. Healthcare providers, with intimate knowledge of their patients’ healthcare needs, should have all current, front-line treatments available to prescribe.

For many people with hepatitis B, TAF is the best and only option for treatment. TAF is less likely to cause adverse effects on bone mineral density and renal dysfunctions than tenofovir disoproxil fumarate (TDF). By removing Vemlidy from the formulary plan, CVS Health is implementing a significant barrier to thousands of Americans at risk for these complications who may need and/or rely on this drug to manage their hepatitis B. The decision to remove Vemlidy as an option for individuals forces “non-medical switching,” where a patient must change medications for reasons other than their health. Non-medical switching is associated with poor health outcomes, and higher costs for patients, thereby decreasing accessibility of medications. A 2019 study by the Alliance for Patient Access found that 1 in 10 patients reported being hospitalized for complications after being switched off their preferred medication; and 40% stopped taking their medication completely. A 2017 study concluded that cost-motivated medication switches result in higher non-drug medical costs, such as doctor office visits, hospitalizations, and ER visits.

Download Letter

Metadata